What are the mechanisms, clinical presentation, side‑effect incidence (with percentages), South Asian/Indian epidemiology, diagnostic work‑up, and recommended management—including folinic acid (leucovorin) rescue, hydration, urine alkalinization, glucarpidase use, and supportive care—for methotrexate toxicity or overdose, particularly regarding emergency department presentation and treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Methotrexate Toxicity and Overdose: Emergency Management

Immediately administer folinic acid (leucovorin) 10 mg/m² IV every 6 hours when methotrexate toxicity is suspected, and continue hydration with urinary alkalinization (pH ≥7.0) until serum methotrexate levels fall below 0.05 micromolar. 1, 2

Mechanisms of Toxicity Development

Methotrexate toxicity develops through renal crystallization in tubular lumens, causing acute kidney injury (AKI) in 2-12% of patients receiving high-dose therapy 3. This creates a vicious cycle: impaired renal clearance (85% of methotrexate is renally excreted) → prolonged drug exposure → worsening nephrotoxicity → further accumulation 1, 4.

Key Risk Factors for Toxicity:

  • Renal insufficiency (most critical)
  • Advanced age
  • Lack of folate supplementation
  • Dosing errors (especially daily instead of weekly dosing)
  • Drug interactions (NSAIDs, sulfonamides, trimethoprim, penicillins)
  • Hypoalbuminemia
  • Dehydration/acidic urine
  • Alcohol consumption 1, 5

Emergency Department Presentation

Chief Complaints by Timeline:

Within 12-24 hours:

  • Nausea, vomiting (occurs in up to 25% of patients) 5
  • Anorexia
  • Fatigue

Days 3-7:

  • Mucositis/stomatitis (oral ulcers)
  • Diarrhea
  • Fever
  • New cough (pulmonary toxicity warning sign)

Days 5-14:

  • Bleeding/bruising (thrombocytopenia)
  • Infections (neutropenia)
  • Jaundice (hepatotoxicity)
  • Oliguria/anuria (AKI) 1

Mortality Data

Of 164 methotrexate-associated fatalities:

  • 41% (67 deaths) from myelosuppression
  • 18% (30 deaths) from pulmonary fibrosis
  • 5% (8 deaths) from hepatotoxicity 1

Diagnostic Work-Up

Immediate Laboratory Assessment:

  1. Serum methotrexate level (critical—measure at least daily)
  2. Complete blood count with differential
  3. Serum creatinine and BUN
  4. Calculate eGFR (creatinine alone unreliable in elderly/low muscle mass)
  5. Liver enzymes (AST, ALT, alkaline phosphatase, albumin)
  6. Urine pH (must maintain ≥7.0)
  7. Electrolytes 1, 6

Critical Methotrexate Levels Indicating Toxicity:

  • ≥10 micromolar at 24 hours post-dose
  • ≥1 micromolar at 48 hours
  • >0.2 micromolar at 72 hours
  • >0.05 micromolar at 96 hours 2

Treatment Algorithm

Step 1: Immediate Supportive Care (ALL Patients)

Hydration:

  • IV fluids at 3 liters/day minimum
  • Target urine output >100 mL/hour

Urinary Alkalinization:

  • Sodium bicarbonate IV to maintain urine pH ≥7.0
  • Monitor pH every 6 hours 2, 3, 4

Step 2: Leucovorin (Folinic Acid) Rescue

Standard Dosing:

  • 15 mg IV/IM/PO every 6 hours starting 24 hours after methotrexate
  • Continue for 10 doses (60 hours total) if normal elimination 2

Escalated Dosing for Delayed Elimination:

Clinical Scenario MTX Level Leucovorin Dose
Delayed late elimination >0.2 µM at 72h or >0.05 µM at 96h 15 mg IV q6h until <0.05 µM
Delayed early elimination or AKI ≥50 µM at 24h OR ≥5 µM at 48h OR creatinine doubled 150 mg IV q3h until <1 µM, then 15 mg q3h until <0.05 µM

2

Critical Timing: Leucovorin effectiveness decreases with time—administer immediately when toxicity suspected. Do not wait for levels. 1

Step 3: Glucarpidase (Carboxypeptidase-G2)

Indications:

  • Serum methotrexate ≥50 micromolar at 24 hours OR ≥5 micromolar at 48 hours
  • Creatinine increase ≥100% within 24 hours of methotrexate
  • AKI with impaired methotrexate clearance 3, 4, 7

Dosing:

  • Standard: 50 units/kg IV (single dose)
  • Emerging evidence supports 25 units/kg with similar efficacy and reduced cost 8
  • Reduces methotrexate by 90-95% within 15 minutes 9, 7

Important: Recent evidence shows folinic acid does NOT interfere with glucarpidase efficacy—do not pause leucovorin rescue 10, 9. However, glucarpidase degrades 8-78% of folinic acid, so consider increasing leucovorin dose post-glucarpidase 10.

Step 4: Renal Replacement Therapy

Consider hemodialysis when:

  • Glucarpidase unavailable
  • Persistent severe toxicity despite glucarpidase
  • Severe AKI requiring dialysis 9

Monitoring During Treatment

First 48 hours:

  • Methotrexate levels every 24 hours
  • CBC daily
  • Creatinine daily
  • Urine pH every 6 hours

After 48 hours:

  • Continue monitoring until methotrexate <0.05 micromolar
  • Watch for pancytopenia (can occur 4-6 weeks after dose increase) 1

Drug Interactions to STOP Immediately

High-risk medications causing toxicity:

  • Trimethoprim-sulfamethoxazole (folic acid antagonist + renal effects)
  • NSAIDs (decrease renal clearance)
  • Penicillins (compete for renal secretion)
  • Proton pump inhibitors (decrease methotrexate clearance)
  • Any nephrotoxic agent 1, 11, 4

South Asian/Indian Subcontinent Considerations

No specific epidemiological data exists for methotrexate toxicity rates in South Asian populations in the provided evidence. However, key considerations include:

  • Genetic polymorphisms in folate metabolism enzymes (MTHFR) may vary by ethnicity—consider lower starting doses
  • Nutritional folate status may differ—ensure adequate supplementation
  • Renal function assessment critical given higher diabetes/hypertension prevalence
  • Drug interactions with traditional medicines—obtain complete medication history including herbal supplements

Common Pitfalls to Avoid

  1. Dosing error confusion: Methotrexate is dosed WEEKLY, not daily—daily dosing causes severe toxicity 1

  2. Delaying leucovorin: Start immediately when toxicity suspected—don't wait for levels 1

  3. Inadequate alkalinization: Urine pH must be ≥7.0, not just "alkaline" 2

  4. Missing drug interactions: Always check for NSAIDs, antibiotics before each dose 1, 11

  5. Ignoring pulmonary symptoms: New cough requires immediate chest X-ray—pulmonary fibrosis causes 18% of methotrexate deaths 1

  6. Relying on creatinine alone: Calculate eGFR, especially in elderly/low muscle mass patients 1, 5

  7. Stopping leucovorin for glucarpidase: Continue folinic acid—it does NOT interfere 10, 9

Prevention Strategies

Before EACH methotrexate dose:

  • Verify weekly (not daily) dosing
  • Check CBC, creatinine, liver enzymes 4-6 days after previous dose (not immediately after) 11
  • Confirm folic acid 1-5 mg daily (except day of methotrexate) 1
  • Review all medications for interactions
  • Ensure adequate hydration status

Test dose recommended: 2.5-5 mg with CBC check 5-6 days later in high-risk patients (renal impairment, elderly) 1

References

Related Questions

What is the recommended time interval between leucovorin and glucarpidase administration?
What is the modern evolution of high-dose methotrexate therapy, including dosing, hydration, urine alkalinization, leucovorin rescue, and glucarpidase use?
In a patient with suspected methotrexate toxicity, should hemodialysis be started immediately, or should treatment begin with intravenous folinic acid (leucovorin) rescue while awaiting serum methotrexate levels?
What are the major toxicities of methotrexate and how should they be monitored?
What is the recommended dosage of folic acid (Vitamin B9) for patients taking high doses of methotrexate?
What is the likely diagnosis and recommended management for a 25‑year‑old male who has had head rocking during sleep since childhood without pain, injury, daytime sleepiness, or neurologic deficits?
Can nighttime muscle pain that began after starting rosuvastatin 20 mg be caused by the statin even though creatine kinase is normal, or does a normal CK exclude statins as the cause?
What is the recommended regimen and monitoring for enoxaparin use for deep‑vein thrombosis prophylaxis in pediatric patients?
What is the appropriate management for a cirrhotic patient with a platelet count of 5 × 10⁹/L?
What is the recommended enoxaparin dosing and anti‑Xa monitoring for thrombosis prophylaxis in pediatric patients with nephrotic syndrome, including adjustments for age and renal function?
What is the appropriate management for a moderately contracted gallbladder?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.